Date: 2013-10-01
Type of information: Commercialisation agreement
Compound: Epi proColon® (colorectal cancer blood test)
Company: Epigenomics (Germany) Polymedco (USA)
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation
Action mechanism:
Disease: colorectal cancer
Details: * On October 01, 2013, Epigenomics has entered into a joint commercialization agreement with Polymedco Inc. Both companies will jointly commercialize Epi proColon®, Epigenomics\' blood-based test for colorectal cancer (CRC) screening, in North America. Under the terms of the agreement, Polymedco will deploy its CRC dedicated sales force and technical support staff, administration, logistics and other support functions to ensure the optimum market introduction and roll-out of Epi proColon® once the test is potentially approved by theFDA. Both parties will work jointly on the marketing, launch and development strategies and with key payers to obtain favorable reimbursement coverage. Epigenomics will retain the responsibility to manufacture the product and to support it from the medical and regulatory point of view, including activities necessary to achieve inclusion in major cancer screening guidelines post approval. A working group comprised of representatives of both companies will oversee the launch and commercial roll-out and engage in activities necessary to ensure the commercial success of the product once it becomes available to the market. The companies agreed to a combined transfer price and profit sharing agreement subject to minimum annual sales of test kits from Epigenomics to Polymedco.
Financial terms:
Latest news:
